Salta al menu principale di navigazione Salta al contenuto principale Salta al piè di pagina del sito
FrancoAngeli Journals

Paper Scientifico

N. 65-66 (2024)

Un nuovo approccio per il trattamento della dipendenza da oppiacei nel contesto italiano. Il parere degli esperti

DOI
https://doi.org/10.3280/mis65-66-2024oa18106
Inviata
10 luglio 2024
Pubblicato
31-07-2024

Riferimenti bibliografici

  1. Albayaty M., Linden M., Olsson H., Johnsson M., Strandgarden K., Tiberg F. (2017). Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study.
  2. Davoli M., Bargagli A., Perucci C., Schifano P., Valeria Belleudi V., Hickman M., Salamina G., Diecidue R., Vigna-Taglianti F., Faggiano F., VEdeTTE Study Group (2007). Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Doi: 10.1111/j.1360-0443.2007.02025.
  3. D’Angela D., Lucchini A. Rapporto OISED 2023.
  4. Dipartimento Politiche Antidroga, Presidenza del Consiglio, Relazioni annuali (anni vari).
  5. Dunlop A.J., White B., Roberts J., Cretikos M., Attalla D., Ling R., Searles A., Mackson J., Doyle M.F., McEntyre E., Attia J., Oldmeadow C., Howard M.V., Murrell T., Haber P.S., Lintzeris N. (2021). Treatment of opioid dependence with depot buprenorfphine (CAM2038) in custodial settings.
  6. EMA - Buvidal Public Assessment Report. www.ema.europa.eu/en/documents/assessment-report/buvidal-epar-public-assessmentreport_en.pdf.
  7. Frost M., Bailey G., Lintzeris N., Strang J., Dunlop A., Nunes E., Jansen J.B., Frey L.C., Weber B., Haber P., Oosman S., Kim S., Tiberg F. (2019). Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder.
  8. Gross G., Conroy S., Leonardi C., Meroueh F., Antolin J.M., Somaini L. (2021). Reducing opioid dependence therapy risk in the prison system and the use of extended-release buprenorphine as an additional treatment option: A consensus statement.
  9. Ling R., White B., Roberts J., Cretikos M., Howard M.V., Haber P.S., Lintzeris N., Reeves P., Dunlop A.J., Searles A. (2022). Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.
  10. Little S., White B., Moensted M., Butler K., Howard M., Roberts J., Dunlop A. (2023). Health and correctional staff acceptability of depot buprenorphine in NSW prisons.
  11. Lofwall M.R., Walsh S.L., Nunes E.V., Bailey G.L., Sigmon S.C., Kampman K.M., Frost M., Tiberg F., Linden M., Sheldon B., Oosman S., Peterson S., Chen M., Kim S. (2018). Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder.
  12. Merrall E., Kariminia A., Binswanger I.A., Hobbs M.S., Farrell M., Mardsen J., Hutchinson S.J., Bird S.M. (2010). Meta-analysis of drug-related deaths soon after release from prison.
  13. Middleton L. et al. (2019). Improved recovery outcomes with injectable prolonged-release buprenorphine in an opioid agonist therapy clinic in Glasgow.
  14. Ministero della Salute, Flusso informativo SIND (anni vari).
  15. Neale J., Tompkins C.N.E., Mcdonald R., Strang J. (2018). Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin. Drug Alcohol Depend., 189: 1-7.
  16. Parida S., Carroll K.M., Petrakis I.L., Sofuoglu M. (2019). Buprenorphine treatment for opioid use disorder: Recent progress. Expert. Rev. Clin. Pharmacol., 12: 791-803.
  17. Reimer J., Wright N., Somaini L., Roncero C., Maremmani I., Mckeganey N., Littlewood R., Krajci P., Alho A., D’Agnone O. The Impact of Misuse and Diversion of Opioid Substitution Treatment Medicines: Evidence Review and Expert Consensus.
  18. Riglietta M. (2020). Impianto sottocutaneo di buprenorfina: revisione della letteratura sul disturbo da uso di oppiacei.
  19. Somaini L., Vecchio S., Corte C., Coppola C., Mahony A., Pitts A., Cutuli M., Orso R., Littlewood R. (2021). Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life. Doi: 10.7759/cureus.18513.
  20. Stover H., Keppler K. (2022). Opioidsubstitutionsbehandlung im Justizvollzug: Der Vergabeaufwand von Buprenorphin-Depot im Vergleich zu anderen Substitutionsmedikamenten – eine gesundheitsökonomische Modellrechnung.
  21. Terrail N., Baffert S., Meroueh F. (2023). Analyse d’impact budgétaire de l’utilisation de la buprénorphine à libération prolongée en milieu carceral.
  22. Tiberg F., Johnsson M. (2011). Drug delivery applications of nonlamellar liquid crystalline phases and nanoparticles.
  23. Tiberg F., Johnsson M., Jankunec M., Barauskas J. Phase Behavior, Functions, and Medical Applications of Soy Phosphatidylcholine and Diglyceride Lipid Compositions.
  24. Tompkins C.N.E., Neale J., Strang J. (2019). Opioid users’ willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
  25. Walsh S., Comer S.D., Lofwall M.R., Vince B., Naama Levy-Cooperman N, Kelsh D., Coe M.A., Jones J.D., Nuzzo P.A., Tiberg F., Sheldon B., Kim S. (2017). Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder A Randomized Clinical Trial.
  26. Wright N., D’Agnone O., Krajci P., Littlewood R., Alho A., Reimer J., Roncero C., Somaini L., Maremmani I. (2015). Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience.
  27. Wright N., Hard J., Fearns C., Gilman M., Littlewood R., Clegg R., Parimelalagan L., Alam F. (2020). OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis.

Metriche

Caricamento metriche ...